Table 1.

Demographics

Characteristic	DA60 (n = 602)	DA90 (n = 604)
Age, y
16-29	59	59
30-39	65	66
40-49	120	121
50-59	199	199
60+	159	159
Median	53	53
Range	16-72	16-72
Sex
Female	267	284
Male	335	320
Diagnosis
De novo	509	509
Secondary	59	59
MDS	34	36
World Health Organization PS
0	401	403
1	165	166
2	20	21
3	15	14
4	1	0
White blood cell count
0-9.9	320	312
10-49.9	175	175
50-99.9	65	65
100+	42	52
Median	8.0	9.3
Range	0.3-430.0	0.4-395.0
Cytogenetics
Favorable	60	52
Intermediate	410	417
Adverse	96	109
Unknown	36	26
FLT3 ITD
WT	458	462
Mutant	100	100
Unknown	44	42
NPM1c
WT	400	383
Mutant	153	167
Unknown	49	54
ITD/NPM1c
ITD WT, NPM1c WT	356	349
ITD WT, NPM1c mutant	97	102
ITD mutant, NPM1c WT	44	34
ITD mutant, NPM1c mutant	56	65
Unknown	49	54
Post–course 1 risk score
Good risk	80	63
Standard risk	255	257
Poor risk	219	214
Not assessable*	48	70

WT, wild-type.

^*Post–course 1 validated risk score²² is not available for patients who had induction death, had missing cytogenetics, or in whom a response to course 1 was not available.